{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T01:42:18Z","timestamp":1791769338781,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84343-x","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:46:37Z","timestamp":1736768797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen"],"prefix":"10.1038","volume":"15","author":[{"given":"Quane","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"5S","key":"84343_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.6004\/jnccn.2018.0040","volume":"16","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. Management of multiple myeloma. J. Natl. Compr. Canc Netw. 16 (5S), 624\u2013627 (2018).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"10272","key":"84343_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397 (10272), 410\u2013427 (2021).","journal-title":"Lancet"},{"issue":"5","key":"84343_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28 (5), 1122\u20131128 (2014).","journal-title":"Leukemia"},{"issue":"1","key":"84343_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.15504","volume":"183","author":"R Oostvogels","year":"2018","unstructured":"Oostvogels, R., Jak, M., Raymakers, R., Mous, R. & Minnema, M. C. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Br. J. Haematol. 183 (1), 60\u201367 (2018).","journal-title":"Br. J. Haematol."},{"issue":"4","key":"84343_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/cells11040606","volume":"11","author":"S Mor\u00e8","year":"2022","unstructured":"Mor\u00e8, S. et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go. Cells 11 (4), 606 (2022).","journal-title":"Cells"},{"key":"84343_CR6","doi-asserted-by":"publisher","first-page":"101100","DOI":"10.1016\/j.blre.2023.101100","volume":"61","author":"D Kegyes","year":"2023","unstructured":"Kegyes, D. et al. Proteasome inhibition in combination with immunotherapies: state-of-the-art in multiple myeloma. Blood Rev. 61, 101100 (2023).","journal-title":"Blood Rev."},{"issue":"20","key":"84343_CR7","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah, J. J. et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126 (20), 2284\u20132290 (2015).","journal-title":"Blood"},{"issue":"8","key":"84343_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/13696998.2019.1614932","volume":"22","author":"M Hagiwara","year":"2019","unstructured":"Hagiwara, M., Panjabi, S., Sharma, A. & Delea, T. E. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone. J. Med. Econ. 22 (8), 818\u2013829 (2019).","journal-title":"J. Med. Econ."},{"issue":"26","key":"84343_CR9","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised International Staging System for multiple myeloma: a Report from International Myeloma Working Group. J. Clin. Oncol. 33 (26), 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"84343_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","volume":"132","author":"RD Dolan","year":"2018","unstructured":"Dolan, R. D., Laird, B., Horgan, P. G. & McMillan, D. C. The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit. Rev. Oncol. Hematol. 132, 130\u2013137 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"84343_CR11","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00277-020-04092-5","volume":"99","author":"A Szudy-Szczyrek","year":"2020","unstructured":"Szudy-Szczyrek, A. et al. Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. Ann. Hematol. 99 (12), 2881\u20132891 (2020).","journal-title":"Ann. Hematol."},{"key":"84343_CR12","doi-asserted-by":"publisher","first-page":"766672","DOI":"10.3389\/fonc.2021.766672","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Are the derived indexes of Peripheral whole blood cell counts (NLR, PLR, LMR\/MLR) clinically significant prognostic biomarkers in multiple myeloma? A systematic review and Meta-analysis. Front. Oncol. 11, 766672 (2021).","journal-title":"Front. Oncol."},{"issue":"1","key":"84343_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar, K., Chauhan, D. & Anderson, K. C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23 (1), 10\u201324 (2009).","journal-title":"Leukemia"},{"issue":"6367","key":"84343_CR14","doi-asserted-by":"publisher","first-page":"eaal5081","DOI":"10.1126\/science.aal5081","volume":"358","author":"C Engblom","year":"2017","unstructured":"Engblom, C. et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF(high) neutrophils. Science 358 (6367), eaal5081 (2017).","journal-title":"Science"},{"issue":"6367","key":"84343_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1126\/science.aar2640","volume":"358","author":"H Zhang","year":"2017","unstructured":"Zhang, H. & Lyden, D. Bone voyage-osteoblasts remotely control tumors. Science 358 (6367), 1127\u20131128 (2017).","journal-title":"Science"},{"issue":"4","key":"84343_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1634\/theoncologist.2017-0354","volume":"23","author":"YK Chae","year":"2018","unstructured":"Chae, Y. K., Oh, M. S. & Giles, F. J. Molecular biomarkers of primary and Acquired Resistance to T-Cell-mediated immunotherapy in Cancer: Landscape, Clinical implications, and future directions. Oncologist 23 (4), 410\u2013421 (2018).","journal-title":"Oncologist"},{"key":"84343_CR17","doi-asserted-by":"publisher","first-page":"639636","DOI":"10.3389\/fimmu.2021.639636","volume":"12","author":"Y Jian","year":"2021","unstructured":"Jian, Y. et al. Current advance of Immune Evasion mechanisms and emerging immunotherapies in Renal Cell Carcinoma. Front. Immunol. 12, 639636 (2021).","journal-title":"Front. Immunol."},{"key":"84343_CR18","doi-asserted-by":"publisher","first-page":"1162211","DOI":"10.3389\/fimmu.2023.1162211","volume":"14","author":"S Yang","year":"2023","unstructured":"Yang, S. et al. Molecular mechanisms and cellular functions of liquid-liquid phase separation during antiviral immune responses. Front. Immunol. 14, 1162211 (2023).","journal-title":"Front. Immunol."},{"key":"84343_CR19","doi-asserted-by":"publisher","first-page":"1345838","DOI":"10.3389\/fimmu.2024.1345838","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu, J., Zhang, B., Zhang, G. & Shang, D. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point. Front. Immunol. 15, 1345838 (2024).","journal-title":"Front. Immunol."},{"issue":"24","key":"84343_CR20","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1182\/blood-2012-06-438598","volume":"120","author":"MS Cho","year":"2012","unstructured":"Cho, M. S. et al. Platelets increase the proliferation of ovarian cancer cells. Blood 120 (24), 4869\u20134872 (2012).","journal-title":"Blood"},{"issue":"10","key":"84343_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1182\/blood-2017-02-769893","volume":"130","author":"MS Cho","year":"2017","unstructured":"Cho, M. S. et al. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood 130 (10), 1235\u20131242 (2017).","journal-title":"Blood"},{"issue":"21","key":"84343_CR22","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-21-1180","volume":"81","author":"B Wu","year":"2021","unstructured":"Wu, B. et al. Megakaryocytes Mediate Hyperglycemia-Induced Tumor Metastasis. Cancer Res. 81 (21), 5506\u20135522 (2021).","journal-title":"Cancer Res."},{"issue":"10","key":"84343_CR23","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-17-2003","volume":"24","author":"S Takagi","year":"2018","unstructured":"Takagi, S. et al. Platelets enhance multiple myeloma progression via IL-1\u03b2 Upregulation. Clin. Cancer Res. 24 (10), 2430\u20132439 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"84343_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1182\/blood.V68.2.514.514","volume":"68","author":"E Fritz","year":"1986","unstructured":"Fritz, E., Ludwig, H., Scheithauer, W. & Sinzinger, H. Shortened platelet half-life in multiple myeloma. Blood 68 (2), 514\u2013520 (1986).","journal-title":"Blood"},{"issue":"3","key":"84343_CR25","doi-asserted-by":"publisher","first-page":"e550","DOI":"10.1038\/bcj.2017.30","volume":"7","author":"L Saeed","year":"2017","unstructured":"Saeed, L. et al. Prognostic relevance of Lymphocytopenia, Monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 7 (3), e550 (2017).","journal-title":"Blood Cancer J."},{"issue":"11","key":"84343_CR26","doi-asserted-by":"publisher","first-page":"e0207224","DOI":"10.1371\/journal.pone.0207224","volume":"13","author":"J Cuello-L\u00f3pez","year":"2018","unstructured":"Cuello-L\u00f3pez, J., Fidalgo-Zapata, A., L\u00f3pez-Agudelo, L. & V\u00e1squez-Trespalacios, E. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLoS One. 13 (11), e0207224 (2018).","journal-title":"PLoS One"},{"issue":"2","key":"84343_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","volume":"23","author":"Y Guan","year":"2020","unstructured":"Guan, Y. et al. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 23 (2), 220\u2013231 (2020).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"84343_CR28","doi-asserted-by":"publisher","first-page":"e0268288","DOI":"10.1371\/journal.pone.0268288","volume":"17","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: a systematic review and meta-analysis. PLoS One. 17 (5), e0268288 (2022).","journal-title":"PLoS One"},{"issue":"12","key":"84343_CR29","doi-asserted-by":"publisher","first-page":"18792","DOI":"10.18632\/oncotarget.13320","volume":"8","author":"L Shi","year":"2017","unstructured":"Shi, L. et al. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget 8 (12), 18792\u201318801 (2017).","journal-title":"Oncotarget"},{"issue":"4","key":"84343_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4103\/JLP.JLP_36_18","volume":"10","author":"S Solmaz","year":"2018","unstructured":"Solmaz, S. et al. Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma. J. Lab. Physicians. 10 (4), 363\u2013369 (2018).","journal-title":"J. Lab. Physicians"},{"issue":"5","key":"84343_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","volume":"20","author":"S M\u00e9ndez-Ferrer","year":"2020","unstructured":"M\u00e9ndez-Ferrer, S. et al. Bone marrow niches in haematological malignancies. Nat. Rev. Cancer. 20 (5), 285\u2013298 (2020).","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"84343_CR32","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/biom13111629","volume":"13","author":"NS Sharma","year":"2023","unstructured":"Sharma, N. S. & Choudhary, B. Good cop, bad cop: profiling the Immune Landscape in multiple myeloma. Biomolecules 13 (11), 1629 (2023).","journal-title":"Biomolecules"},{"issue":"6","key":"84343_CR33","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/jcla.22004","volume":"30","author":"S Wongrakpanich","year":"2016","unstructured":"Wongrakpanich, S. et al. The Prognostic significance of Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with multiple myeloma. J. Clin. Lab. Anal. 30 (6), 1208\u20131213 (2016).","journal-title":"J. Clin. Lab. Anal."},{"issue":"5","key":"84343_CR34","doi-asserted-by":"publisher","first-page":"e22107","DOI":"10.1002\/jcla.22107","volume":"31","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Pretreatment neutrophil\/lymphocyte ratio but not platelet\/lymphocyte ratio has a prognostic impact in multiple myeloma. J. Clin. Lab. Anal. 31 (5), e22107 (2017).","journal-title":"J. Clin. Lab. Anal."},{"issue":"6","key":"84343_CR35","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/sj.leu.2404229","volume":"20","author":"A Mantovani","year":"2006","unstructured":"Mantovani, A. & Garlanda, C. Inflammation and multiple myeloma: the toll connection. Leukemia 20 (6), 937\u2013938 (2006).","journal-title":"Leukemia"},{"issue":"6","key":"84343_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.24352","volume":"91","author":"JA Lust","year":"2016","unstructured":"Lust, J. A. et al. Reduction in C-reactive protein indicates successful targeting of the IL-1\/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am. J. Hematol. 91 (6), 571\u2013574 (2016).","journal-title":"Am. J. Hematol."},{"key":"84343_CR37","doi-asserted-by":"publisher","first-page":"155428","DOI":"10.1016\/j.cyto.2021.155428","volume":"141","author":"W Sayah","year":"2021","unstructured":"Sayah, W. et al. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. Cytokine 141, 155428 (2021).","journal-title":"Cytokine"},{"key":"84343_CR38","doi-asserted-by":"publisher","first-page":"663748","DOI":"10.3389\/fimmu.2021.663748","volume":"12","author":"L Zhaoyun","year":"2021","unstructured":"Zhaoyun, L. & Rong, F. Predictive role of Immune Profiling for Survival of multiple myeloma patients. Front. Immunol. 12, 663748 (2021).","journal-title":"Front. Immunol."},{"issue":"3","key":"84343_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2017-06-742676","volume":"131","author":"B Ho-Tin-No\u00e9","year":"2018","unstructured":"Ho-Tin-No\u00e9, B., Boulaftali, Y. & Camerer, E. Platelets and vascular integrity: how platelets prevent bleeding in inflammation. Blood 131 (3), 277\u2013288 (2018).","journal-title":"Blood"},{"issue":"8","key":"84343_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41577-023-00834-4","volume":"23","author":"M Scherlinger","year":"2023","unstructured":"Scherlinger, M., Richez, C., Tsokos, G. C., Boilard, E. & Blanco, P. The role of platelets in immune-mediated inflammatory diseases. Nat. Rev. Immunol. 23 (8), 495\u2013510 (2023).","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"84343_CR41","doi-asserted-by":"publisher","first-page":"e0271637","DOI":"10.1371\/journal.pone.0271637","volume":"17","author":"X Brands","year":"2022","unstructured":"Brands, X. et al. Immune suppression is associated with enhanced systemic inflammatory, endothelial and procoagulant responses in critically ill patients. PLoS One. 17 (7), e0271637 (2022).","journal-title":"PLoS One"},{"issue":"5","key":"84343_CR42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/ejh.13839","volume":"109","author":"CY Soekojo","year":"2022","unstructured":"Soekojo, C. Y. & Chng, W. J. The evolution of immune dysfunction in multiple myeloma. Eur. J. Haematol. 109 (5), 415\u2013424 (2022).","journal-title":"Eur. J. Haematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84343-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:46:40Z","timestamp":1736768800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84343-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84343"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84343-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Committee of Huai\u2019an No.1 People\u2019s Hospital and was conducted following the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"1819"}}